The company is a leading global pharmaceutical research and development services platform. Headquartered in Shanghai, China, the company provides comprehensive and integrated platform services of discovery, development and manufacturing of small molecule drugs for over 3,700 customers through 29 operation sites and branch offices across the globe, including in China, U.S. and Europe. It provides global pharmaceutical companies with discovery, manufacturing and supporting services of new drugs through a platform covering the entire industry chain, and also offers certain testing services for medical devices as well as research, development and manufacturing services of precision medicine. From January to September 2019, the company recorded revenue of approximately RMB 9.279 billion, up 34.06 YoY, there was a rapid growth of each business segment; net profit attributable to shareholders of the company was RMB1.765 billion, down 8.46% YoY, which was mainly due to a significant decrease of RMB714.22 million in the fair value change of invested portfolio companies, from a gain of RMB668.82 million for the corresponding period of the previous year to a loss of RMB45.40 million. In the future the company will accelerate the development and manufacturer of new products, drive rapid growth of key new products and increase market share and coverage of products from different business segments to promote performance.
Buy-in Price: $100, Target Price: $110, Cut Loss Price: $95
Taiko Pharmaceutical Co., Ltd. (4574)
Established in 1946. Succeeded the manufacturing and retail rights of Chuyu Seirogan (currently ¡§Seirogan¡¨). Expands 3 businesses, which are ¡§Pharmaceuticals¡¨, which carry out the manufacture and retail of general pharmaceuticals, ¡§Infection Management¡¨, which utilizes patented technology involving chlorine dioxide gas, and ¡§Others¡¨.For 1H (Apr-Sep) results of FY2020/3 announced on 8/11, net sales increased by 14.6% to 4.385 billion yen compared to the same period the previous year and operating income increased by 52.3% to 980 million yen. Sales of the ¡§Leave-on-type Cleverin¡¨ and ¡§Cleve & And¡¨ in their infection management business have performed strongly. The 27.3% increase in net sales to 1.675 billion yen and the 2.8 times increase in segment profits to 434 million yen in this business have also contributed to an increase in both sales and profit.For its full year plan, net sales is expected to increase by 8.1% to 11.26 billion yen compared to the previous year and operating income to increase by 8.4% to 2.2 billion yen. Shipments in their pharmaceutical business for the Chinese market are planned to begin from Oct 2019. In addition, due to an increase in brand awareness from the marketing strategy to remove the ¡§trumpet logo¡¨ in the infection management business, as well as a rise in demand for virus elimination / disinfectants such as influenza in the office, we can expect a sustained popularity for Cleverin.Target Price : 3,300 yenBuy Price : 3,040 yenCut-Loss : 2,900 yen
CH ENERGY ENG (3996.HK) - Newly signed contracts keep growing
Since November 2019, the company and its subsidiaries have signed or awarded a number of new projects, including four domestic projects involving an investment of approximately RMB17.2 billion; eight overseas projects mainly focus on power station projects. Major projects include: 1) China Energy Engineering Group Guangdong Power Engineering Co., Ltd., a subsidiary of China Energy Engineering Group Southern Construction & Investment Co., Ltd. has entered into an EPC contract for the Baltic Sea 324.8MW Wind Farm Project in Poland. The project is located in Słupsk, Poland near the Baltic Sea, and includes 5 specific projects, Its main work comprises power station EPC construction, which includes designing services, manufacturing, supervising, testing, equipment supplying, whole factory constructing, installing, debugging, training, spare parts within the warranty period, consumables and services, etc. The contract amount of the project is approximately EUR568 million. 2) The project is located in Umm Al Quwain, United Arab Emirates. Its main work comprises the construction of a seawater desalination plant with a daily production capacity of 150MIG (approximately 682,000 tonnes/day), including the design, procurement, construction, debugging and testing of seawater intake and drainage ancillary facilities and water storage tanks. The total contract amount of the project is approximately USD625 million, of which the contract amount of Gezhouba International Co. is approximately USD369.5 million. The contract term is 33 months, commencing from the date of construction. 3) The project company is jointly established by the government-funded representative and the social investor, and is responsible for the unified operation. The total investment of the project is approximately RMB5.732 billion, and the term of cooperation is 30 years, including 4 years of construction period and 26 years of operation period. 4) a subsidiary and cooperating parties has entered into an EPC contract for the 1000MW Oil and Gas Combined Cycle Power Station Project in Maysan, Iraq.The project is situated in Maysan Governorate, Iraq. Its main works comprise the design, procurement, and construction of the 1000MW Oil and Gas Power Station. The contract amount of the Project is approximately USD1,200 million. The contract term is 36 months. According to the National Bureau of Statistics, the cumulative annual growth rate of China's fixed asset investment was 5.2% in October 2019, maintaining moderate growth. However, the current downward pressure on the economy is increasing, government is expected to continue introducing relevant policies to increase the infrastructure investment to drag the bottom of the economy. In addition, the monetary policy remains stable and loose, which will benefit the development of the infrastructure sector. We expect that the new contract value of the company will continue to grow steadily.
Signed strategic cooperation agreements with SHIG and Sansha city's government to promote business transformation and development
On November 19, 2019, the signing ceremony of the strategic cooperation framework agreement between China Energy Construction Group Co., Ltd. and Sansha City Government was held in Sansha. According to the agreement, the two sides will carry out comprehensive cooperation in the areas of infrastructure construction and ecological protection in Sansha City, and jointly advance the implementation of relevant major projects. On July 26, 2019, the company has entered into a strategic cooperation framework agreement with Shandong Heavy Industry Group Co., Ltd. (SHIG). Both parties unanimously agreed to establish a comprehensive strategic co-operative partnership in various aspects such as engineering construction and equipment procurement, international business, high-end equipment and industrial park construction, new energy, capital cooperation, technological services as well as talent cooperation. The two parties would fully utilize their respective advantages in various aspects such as their technology, capital, talents, management, market and resources, achieving a win-win situation with mutual benefits and joint development. It is understood that SHIG is a Shandong Provincial state-owned enterprise, and is a Chinese leading and internationally renowned automobile and equipment manufacturing group. The company actively explores cooperation opportunities, seeks business transformation and development, and lays the foundation for new performance growth points in the future.
Adjust TP to HKD 1.05, degrade to "ACCUMULATE" rating
We adjusted target price to HKD 1.05, corresponding to FY19/FY20/FY21 6.34x/5.94x/5.62x PE, which was +17.98% higher than the current price (HKD 0.89 as of December 13, 2019), degrading to ¡§ACCUMULATE¡¨ rating.
International business fails expectations;
China infrastructure investment fails expectations;
China electricity investment fails expectations;
Click Here for PDF format...
|Recommendation on 19-12-2019|
|Price on Recommendation Date||$ 0.890|
|Suggested purchase price||N/A|
|Target Price||$ 1.050|
| H share
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.
If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.
Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.